Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer

Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that failed to respond to docetaxel and cabazitaxel. He subsequently received a third line of chemotherapy with cyclophosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe current treatment options for metastatic prostate cancer
  • Discuss the potential for major response to cyclophosphamide and prednisone in recurrent castrate-resistant prostate cancer (CRPC)
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
08/22/2013
Course expires: 
08/22/2014
Cost:
$0.00

Nicolas Batty, MD, FACP, FASCP
Department of Medicine
Roswell Park Cancer Center
Buffalo, New York

Naveen Yarlagadda, MD
Department of Medicine
Roswell Park Cancer Center
Buffalo, New York

Roberto Pili, MD
Department of Medicine
Roswell Park Cancer Center
Buffalo, New York

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing